Prevent Blindness is currently developing new educational materials on macular telangiectasia. We recognize that no one understands the impact of MacTel better than those who are living with it, so we want to hear from you! If you have MacTel and would like to contribute you insight and experiences to help us create effective resources, [Read More]
Category: Latest News
Opportunity to Participate in Paid Geographic Atrophy Study
Global Perspectives is looking for people with advanced dry AMD (age-related macular degeneration), also known as geographic atrophy (GA). The purpose of this study is to understand patients’ views and preferences related to treatments for geographic atrophy including some that are in development. No treatments will be administered in this study, as only opinions are [Read More]
Genentech to Reintroduce Susvimo for People With Wet AMD
The FDA has approved updates to Susvimo, which will be available to U.S. retina specialists and patients with wet AMD in the coming weeks. Genentech announced today the reintroduction of Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people in the United States with wet, or neovascular, age-related [Read More]
Opportunity for People Affected by Geographic Atrophy
For persons with Geographic Atrophy due to Dry Age-related Macular Degeneration: Lagrippe Research is inviting three individuals diagnosed with Geographic Atrophy to participate in our upcoming discussion. We are also interested in speaking with family members / loved ones that assist and support people who have been diagnosed with GA. The research’s purpose is to [Read More]
Apellis is seeking potential participants for its Patient Ambassador Program
Apellis is seeking potential participants for its Patient Ambassador Program. As part of the program, participants will take part in trainings for the preparation of events where they may share about their geographic atrophy (GA) journey. Please understand that a limited number of individuals will be selected to participate. Apellis staff will talk with you [Read More]